Ixico (AIM:IXI), the AIM-listed neuroscience imaging and biomarker analytics company, has upgraded its full-year revenue guidance, now expecting at least £8 million for the year ending 30 September, ahead of existing market expectations.
The revised figure represents approximately 22% growth on FY 2025 revenues, stepping up from a previous forecast of £7.5 million that had implied 15% growth.
The company attributed the upgrade to strong trading across a widening client base, alongside contract wins and extensions.
"The strong performance has been driven by a continued uplift in contract wins, contract extensions, and revenue diversification," said CEO Bram Goorden, adding that the outcome reflects a strategy put in place in 2024 that is "clearly demonstrating the fruits of that strategy as it matures."
Ixico's full financial results for FY 2026 are due after the year-end on 30 September.
